7963.T
The company operates in the healthcare sector, specializing in medical equipment, supplies, and distribution, generating revenue primarily through the sale and service of medical devices and related products.
Business. The company operates in the healthcare sector, specializing in medical equipment, supplies, and distribution, generating revenue primarily through the sale and service of medical devices and related products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, specializing in medical equipment, supplies, and distribution, generating revenue primarily through the sale and service of medical devices and related products.
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.42, indicating a relatively low reliance on debt financing. Its liquidity position is characterized by a current ratio of 2.22, suggesting the ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
Profitability metrics show a return on equity (ROE) of 6.42% and a return on assets (ROA) of 3.94%, which are below the industry median for medical equipment and supplies firms. The company's gross margin is 45.4%, while its operating margin is 10.7%, both of which are in line with the industry average. The price-to-earnings (P/E) ratio of 10.15 is lower than the industry median, suggesting the stock may be undervalued relative to earnings.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue is primarily derived from domestic operations, with no material international revenue reported.
The company's growth trajectory is modest, with no significant revenue growth reported in the latest fiscal year. The outlook for the next fiscal year is neutral, with no material changes expected in revenue or earnings. The company's capital expenditure is negative, indicating a reduction in investment in physical assets, which may signal a focus on cost control rather than expansion.
The company's risk profile is moderate, with a low dilution potential and a medium liquidity risk. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, which could impact its ability to fund operations without external financing. The company has not issued new shares recently, and there is no indication of dilution pressure in the near term.
Recent events include the filing of the latest financial results, which show a net income of 885.29 million JPY and a revenue of 11.86 billion JPY. The company has not disclosed any material changes in its business operations or strategic direction in the latest filings. Analysts have confirmed the company's earnings and revenue figures, aligning with the reported financial performance.
- The company has a conservative capital structure with a debt-to-equity ratio of 0.42.
- The company's ROE of 6.42% is below the industry median, indicating room for improvement in profitability.
- The company's revenue is concentrated in a single business segment, increasing exposure to regional and regulatory risks.
- The company's growth trajectory is modest, with no significant revenue growth reported in the latest fiscal year.
- The company's liquidity position is moderate, with a current ratio of 2.22 but a negative net cash position after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 7963.T Market data — financials · 2026-05-27
- Koken Ltd Market data — analyst estimates · 2026-05-27